Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5191-4. doi: 10.1016/j.bmcl.2010.07.005. Epub 2010 Jul 8.

Abstract

This communication describes the synthesis and in vitro biological evaluation of novel generation 5 PAMAM dendrimers conjugated with riboflavin as a targeting ligand. Cell-based experiments demonstrated that a dendrimer conjugated with riboflavin is able to undergo cellular binding and uptake in KB cells, and when the dendrimer is also conjugated with methotrexate, the riboflavin dendrimer conjugate can potently inhibit cell growth.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cell Division / drug effects
  • Dendrimers / pharmacology*
  • Drug Design
  • Drug Evaluation, Preclinical
  • HeLa Cells
  • Humans
  • Nanotechnology*
  • Neoplasms / drug therapy*
  • Riboflavin / chemistry*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • Dendrimers
  • PAMAM Starburst
  • Riboflavin